Drug discovery and mutant p53

Trends in Cell Biology
Magda M Maslon, Ted R Hupp

Abstract

Missense mutations in the p53 gene are commonly selected for in developing human cancer cells. These diverse mutations in p53 can inactivate its normal sequence-specific DNA-binding and transactivation function, but these mutations can also stabilize a mutant form of p53 with pro-oncogenic potential. Recent multi-disciplinary advances have demonstrated exciting and unexpected potential in therapeutically targeting the mutant p53 pathway, including: the development of biophysical models to explain how mutations inactivate p53 and strategies for refolding and reactivation of mutant p53, the ability of mutant p53 protein to escape MDM2-mediated degradation in human cancers, and the growing 'interactome' of mutant p53 that begins to explain how the mutant p53 protein can contribute to diverse oncogenic and pro-metastatic signaling. Our rapidly accumulating knowledge on mutant p53-signaling pathways will facilitate drug discovery programmes in the challenging area of protein-protein interactions and mutant protein conformational control.

References

Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N R RodriguesD P Lane
Jun 21, 1991·Science·S E KernB Vogelstein
Feb 13, 1990·Biochemistry·I LalezariM F Perutz
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·I LalezariM F Perutz
May 1, 1993·Nature Genetics·D DittmerA J Levine
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·J A PietenpolB Vogelstein
Jul 11, 1993·Nucleic Acids Research·T R HuppD P Lane
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·M V BlagosklonnyL Neckers
May 15, 1997·Nature·Y HauptM Oren
May 15, 1997·Nature·M H KubbutatK H Vousden
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·A N BullockA R Fersht
Aug 17, 2001·The Journal of Biological Chemistry·Y PengJ Chen
Jan 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Assaf FriedlerAlan R Fersht
Mar 5, 2002·Nature Medicine·Vladimir J N BykovGalina Selivanova
May 15, 2002·Human Mutation·Magali OlivierPierre Hainaut
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Natalia IssaevaGalina Selivanova
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu
Apr 3, 2004·Nature·Jordan M CumminsBert Vogelstein
Apr 30, 2004·Cell Stress & Chaperones·Holly McDonough, Cam Patterson
Jul 29, 2004·Cancer Biology & Therapy·Chad A CorcoranM Saeed Sheikh
Sep 11, 2004·The Journal of Biological Chemistry·Dawid WalerychMaciej Zylicz
Feb 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·George KontopidisMalcolm D Walkinshaw
May 17, 2005·Cancer Cell·Janet PlesciaDario C Altieri

❮ Previous
Next ❯

Citations

Nov 30, 2013·Pharmacology & Therapeutics·Frédéric Checler, Cristine Alves da Costa
Mar 30, 2011·Nature Chemical Biology·Jie XuJoost Schymkowitz
Mar 3, 2011·PloS One·Krishna Sumanth GhantaRakesh Kumar
Jul 20, 2012·Archives of Toxicology·José M MatésJavier Márquez
Jan 10, 2012·Biochemical Pharmacology·Michelle Martinez-Rivera, Zahid H Siddik
Jan 1, 2012·Molecular Informatics·Matteo Floris, Stefano Moro
Dec 17, 2014·Journal of Internal Medicine·J Zawacka-Pankau, G Selivanova
Feb 7, 2015·Cell Cycle·Anne-Sophie TournillonRobin Fåhraeus
Apr 12, 2016·Frontiers in Oncology·Maria FerraiuoloSabrina Strano
Mar 22, 2014·Cancer Cell·Patricia A J Muller, Karen H Vousden
Jul 31, 2012·Biochemical and Biophysical Research Communications·Johanna HasmatsJoakim Lundeberg
Dec 25, 2012·Biochemical Pharmacology·Joana Dias AmaralCecília Maria Pereira Rodrigues
Apr 29, 2016·Proteomics. Clinical Applications·Benjamin A KatchmanKaren S Anderson
Sep 2, 2016·Journal of Agricultural and Food Chemistry·Zhaohui XueXiaohong Kou
Sep 1, 2012·Cell Death and Differentiation·D-Y KimK-T Kim
Jun 11, 2016·Oncotarget·Chung-Hsin ChenYeong-Shiau Pu
Sep 27, 2019·Experimental and Therapeutic Medicine·Zongjuan LiLijuan Zou
Sep 12, 2018·Cancers·Ying ZhangRoger Abounader
Apr 21, 2020·World Journal of Gastroenterology : WJG·Florian BürtinMichael Linnebacher
Nov 15, 2016·The Journal of Pathology. Clinical Research·Martin KöbelJames D Brenton
Feb 2, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shoumin ZhuWael El-Rifai
Jan 4, 2017·Journal of Chemical Theory and Computation·Joseph A MorroneKen A Dill
Feb 22, 2011·Biochemistry·Daniel A Bonsor, Eric J Sundberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Cell Migration in Cancer and Metastasis

Migration of cancer cells into surrounding tissue and the vasculature is an initial step in tumor metastasis. Discover the latest research on cell migration in cancer and metastasis here.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Adenomatous Polyposis Coli

Adenomatous polyposis coli is a protein encoded by the APC gene and acts as a tumor suppressor. Discover the latest research on adenomatous polyposis coli here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Nature Reviews. Molecular Cell Biology
Karen H Vousden, David P Lane
Cold Spring Harbor Perspectives in Biology
Ana I Robles, Curtis C Harris
Cell Death and Differentiation
M F Lavin, N Gueven
Cell Cycle
Nicola J MacLaine, Ted R Hupp
Cold Spring Harbor Perspectives in Biology
David W Meek, Carl W Anderson
© 2021 Meta ULC. All rights reserved